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Abstract
Background: Widespread cortical atrophy in Amyotrophic Lateral Sclerosis (ALS) has been described in
neuropathological studies. The presence of cortical atrophy in conventional and scientific neuroimaging has
been a matter of debate. In studies using computertomography, positron emission tomography, proton
magnetic resonance spectroscopy and conventional T2-weighted and proton-weighted images, results
have been variable. Recent morphometric studies by magnetic resonance imaging have produced
conflicting results regarding the extent of grey and white matter involvement in ALS patients.
Methods: The authors used optimized voxel-based morphometry as an unbiased whole brain approach
to detect differences between regional grey and white matter volumes. Seventeen patients with a diagnosis
of ALS according to El-Escorial criteria and seventeen age-matched controls received a high resolution
anatomical T1 scan.
Results: In ALS patients regional grey matter volume (GMV) reductions were found in the pre- and
postcentral gyrus bilaterally which extended to premotor, parietal and frontal regions bilaterally compared
with controls (p < 0.05, corrected for the entire volume). The revised ALS functional rating scale showed
a positive correlation with GMV reduction of the right medial frontal gyrus corresponding to the
dorsolateral prefrontal cortex. No significant differences were found for white matter volumes or when
grey and white matter density images were investigated. There were no further correlations with clinical
variables found.
Conclusion: In ALS patients, primary sensorimotor cortex atrophy can be regarded as a prominent
feature of the disease. Supporting the concept of ALS being a multisytem disorder, our study provides
further evidence for extramotor involvement which is widespread. The lack of correlation with common
clinical variables probably reflects the fact that heterogeneous disease processes underlie ALS. The
discrepancy within all published morphometric studies in ALS so far may be related to differences in
patient cohorts and several methodological factors of the data analysis process. Longitudinal studies are
required to further clarify the time course and distribution of grey and white matter pathology during the
course of ALS.
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Background
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegen-
erative disease which leads to death due to neurogenic
muscle weakness within a median time span of three years
[1]. Patients clinically develop a paralysis with signs of
upper and lower motoneuron loss in limb, trunk and bul-
bar regions. Oculomotor neurons are spared [2] and neu-
rons of Onuf's nucleus are only slightly affected [3].
Beyond motor deficits, recent reports have described fron-
tal dysfunction to be present in approximately 1/3 of ALS
patients [4]. Overlap syndromes exist, such as ALS-Parkin-
son-Dementia Complex of Guam where an association
with a food chain concentration of the neurotoxic amino
acid beta-methylamino-l-alanine (BMAA) [5] has been
found. Familial cases constitute 5 – 10% of cases which
are caused by mutations of the human superoxide dis-
mutase in 20% of familial ALS [6,7]. A recent histopatho-
logic study revealed an overlap of hallmarks of ALS,
frontotemporal dementia (FTP) and Alzheimer's disease
(AD) in a cohort of patients clinically diagnosed as having
ALS [8]. The ALS disease process therefore seems to
involve areas beyond the upper motoneuron regions of
the cortex and may be the result of heterogenous patho-
logical cellular processes affecting specifically vulnerable
neurons both in the spinal cord and the cortex.
Magnetic resonance imaging studies (MRI) in ALS are
clinically used to exclude other diseases of the brain.
Abnormal signal hyperintensity along the corticospinal
tract (CST) in T2-weíghted and proton density (PD)
images have been described in ~40% of ALS cases as early
as 1991 [9]. Later on, these findings have been seen in ~2/
3 of ALS patients [10]. PD images have been found to be
slightly more sensitive than T2 images in detecting ALS
related CST changes in a study including post-mortem fol-
low-up [4] which described distinct myelin pallor and
gliosis as the histological correlate. FLAIR images dis-
played a hyperintense signal with a higher specificity than
other modalities along the descending pyramidal tract of
ALS patients [11]. More recently, group comparisons
using statistical parametric mapping (SPM) on diffusion
tensor images (DTI) have shown changes along the corti-
cospinal tract which correlated well with the clinical dis-
tribution of motor deficits in ALS patients [12,13].
In contrast to definite abnormal findings along the CST,
studies of cortical atrophy in ALS as detected by MRI have
produced conflicting results. On conventional MRI, an
abnormally large central sulcus can be often be found as
indirect marker of precentral gyrus atrophy [14]. In addi-
tion, serial computertomography (CT) and MR imaging
showed frontal and limbic system atrophy in ALS [15].
MR spectroscopy revealed abnormal ratios of N-acety-
laspartate (NAA) to creatine (Cr) as a marker of neuronal
loss in the motor cortex in ALS patients [14,16,17]. Other
Imaging modalities such as [11C] flumazenil position
emission tomography (PET) [18] displayed a reduced
GABAA binding in parietal to frontal areas. This finding is
supported by histological evidence of reduced expression
of the alpha1-subunit of the GABAA receptor in ALS motor
cortex [19].
Recently, voxel-based analyses of proton density images
MRI have demonstrated predominant frontal cortex atro-
phy in ALS patients but have failed to localize atrophy in
the motor cortex [20,21] whereas other authors showed
primary motor and extramotor involvement to varying
degrees by different methods of voxel based morphome-
try [22,23].
Voxel based morphometry (VBM) is a fully automated,
operator-independent whole brain image analysis tech-
nique that allows the voxel-wise comparison of seg-
mented grey and white matter images between two groups
of subjects [24-26]. It has the advantage that macroscopic
differences are discounted using normalization, and dif-
ferences in local tissue composition can be explored with-
out resorting to the use of manually placed regions of
interest. Furthermore, no a priori hypothesis regarding the
localization of group differences is required. VBM has
been recently refined and successfully used to study struc-
tural brain correlates of aging and changes of grey and
white matter volumes in different neurodegenerative dis-
eases [27-29].
The aim of the present study was to identify possible struc-
tural brain alterations in a group of mildly affected ALS
patients in comparison to normal controls, and to inves-
tigate the correlations of anatomical changes with relevant
clinical variables by using VBM.
Methods
Clinical base
19 patients were recruited from the ALS outpatient clinic
of the department of Neurology, Medical School Hanno-
ver, where they were classified as having definite, proba-
ble, possible or suspected ALS according to the original El
Escorial criteria [30]. Suspected ALS was included to allow
early disease stage patients to enter the study as epidemi-
ology has suggested a high probability of correct initial
diagnosis [31]. In two patients MRI was not performed;
one was too heavy for the MRI table and the other did not
tolerate lying horizontally due to breathing difficulty. All
but one patient progressed to definite or probable ALS
according to the revised El Escorial criteria [32] on follow
up which is now considered a requirement to include
patients into clinical trials. Of the 17 patients in which
MRI was done, mean (± S.D.) duration since onset of
symptoms, in the following termed disease duration, at
MRI was 24 ± 9 months, mean age 61 ± 13 (range 34–77)BMC Neurology 2006, 6:17 http://www.biomedcentral.com/1471-2377/6/17
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years and the revised ALS functional rating scale [33]
Table 1: Demographic information
patient # age (yrs.) sex disease duration (mths.) onset ALSFRS-R at MRI clinical diagnosis (EL Escorial)
1 59 m 30 limb 43 possible
2 59 m 13 limb 37 probable
3 31 m 17 limb 42 probable
4 68 m 22 bulbar 40 definite
5 65 m 25 limb 37 probable
6 66 f 41 limb 28 definite
7 53 m 38 limb 43 suspected
8 34 f 18 bulbar 39 probable
9 75 m 14 limb 44 suspected
10 62 m 18 bulbar 40 probable
11 49 m 19 limb 41 suspected
12 73 m 24 bulbar 33 definite
13 60 m 30 limb 33 probable
14 77 m 34 limb 33 probable
15 63 f 12 bulbar 45 probable
16 66 m 23 limb 48 suspected
17 72 m 25 bulbar 48 probable
mean ± S.D. 61 ± 13 f/m: 3/14 24 ± 09 b/l: 6/11 40 ± 06
Patients with suspected ALS were included in the study. All but one patient (#16) progressed to probable and definite ALS according to the El 
Escorial criteria on follow-up examination.
S.D. = standard deviation; f = female; m = male; b = bulbar; l = limb
Table 2: Clinical scores
# RUE 
(75)
LUE 
(75)
RLE 
(45)
LLE 
(45)
UE 
(150)
LE 
(90)
all E. 
(240)
fasc. 
(0–42)
atr. 
(0–30)
bulb. 
(0–14)
Bab. 
(0–2)
spast. 
(0–32)
refl. 
(0–13)
ALSFRS
-R PR/
mth(6)
ALSFRS
-R PR/
mth(t)
1 68 69 41 41 137 82 219 5 7 2 0 0 0 0.5 0.2
2 75 64 31 27 139 58 197 7 4 0 0 0 0 1.8 0.8
3 64 62 45 45 126 90 216 15 8 0 2 0 12 1.2 0.4
4 75 73 45 42 148 87 235 10 2 2 2 4 4 0.7 0.4
5 72 75 26 16 147 42 189 15 8 0 1 0 6 0.7 0.4
6 67 59 14 13 126 27 153 4 6 0 0 0 6 1.2 0.5
7 74 75 26 23 149 49 198 12 2 0 0 0 0 0.2 0.1
8 70 71 45 45 141 90 231 1 2 4 2 0 12 1.0 0.5
9 60 60 36 39 120 75 195 17 6 0 0 0 0 1.0 0.3
10 63 73 45 45 136 90 226 6 5 4 0 0 12 0.7 0.4
11 54 55 45 45 109 90 199 4 6 0 2 0 0 0.3 0.4
12 58 43 38 38 101 76 177 11 10 3 2 0 6 0.5 0.6
13 58 57 45 45 115 90 205 8 7 2 2 0 5 1.5 0.5
14 70 71 22 37 141 59 200 7 6 0 2 2 12 1.7 0.4
15 75 75 45 45 150 90 240 1 0 3 0 0 11 0.2 0.3
16 61 71 44 44 132 88 220 9 8 0 1 0 0 0.0 0.0
17 69 71 40 41 140 81 221 6 4 3 2 4 6 1.0 0.3
mean 66.6 66.1 37.2 37.1 132.8 74.4 207.1 8.1 5.4 1.4 1.1 0.6 5.4 0.82 0.38
± S.D. 6.7 9.0 9.9 10.6 14.6 19.9 22.3 4.7 2.7 1.6 1.0 1.4 4.9 0.54 0.20
∆ norm 
(%)
-11% -12% -17% -18% -11% -17% -14% 19% 18% 10% 53% 2% 42%
MRC sum scores were used to describe muscle strength for right upper (RUE), left upper (LUE), right lower (RLE), left lower (LLE), upper (UE) and 
lower (LE) and all extremities (all E., see methods); disease related strength reduction is displayed as percent in the lower row. Sum scores of 
fasciculations, atrophy, bulbar signs, Babinski sign, spasticity and reflexes are represented as pathologic increase; the lower row values show percent 
of maximal pathologic scores. ALSFRS progression rates per month are calculated for the 6 months prior to MRI [PR/mth(6)] and the total disease 
duration [PR/mth(t)].BMC Neurology 2006, 6:17 http://www.biomedcentral.com/1471-2377/6/17
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(ALSFRS-R) 40 ± 6 points. The female to male ratio was
3:14; six patients had a bulbar onset and 11 patients limb
onset of weakness. Seventeen age matched (p = 0.89, stu-
dent's t-test) healthy controls (mean age 58 ± 9.4, range
38–68, 7 females) were also studied. Neither patients nor
controls had a history of cerebrovascular disease, long-
standing hypertension or inflammatory disease of the
central nervous system (CNS). All patients were on rilu-
zole; none were taking psychoactive drugs. Written
informed consent was obtained from all participants
according to the approval of the ethics committee of the
Medical School Hannover.
Clincal status
ALSFRS-R progression rate per month was calculated for
the total disease duration [PR/mth(t)] and the six month
period prior to MRI [PR/mth(6)]. Sum scores of Medical
Research Council (MRC) muscle strength were taken for
the upper extremity (shoulder abduction, inward and out-
ward rotation; elbow flexion and extension; lower arm
pronation and supination; wrist flexion and extension;
finger flexion, extension, abduction and adduction; 5th
finger abduction and thumb opposition; best possible
score 75 points) and the lower extremity (hip strength;
knee flexion and extension; foot flexion, extension, inver-
sion and eversion; toe flexion and extension; best possible
score 45 points). Bulbar involvement was described as a
sum score of dysarthria (0 = no, 1 = yes), dysphagia (0 =
no, 1 = yes), eyelid closure, mouth closure, tongue move-
ment and palate elevation (0 = normal, 1 = reduced, 2 =
weak, 3 = absent) with a worst possible score of 14. In a
similar fashion, muscle fasciculations (upper arm, lower
arm, hand, upper thigh, lower thigh and foot of both
sides; rump and tongue; worst score of 42) and muscle
atrophy (upper arm, lower arm, hand, upper thigh, lower
thigh both sides; worst score of 30) were quantified (0 =
normal, 1 = discreet, 2 = moderate, 3 = pronounced).
Reflexes were summed by counting the number of mus-
cles scoring 3 or 4 on the NINDS reflex scale for the
biceps, triceps, brachialis, finger flexors, quadriceps and
gastrocnemius muscles on both sides and masseter mus-
cle (worst score 13). Spasticity was described as normal
(0), noticeable (1), pronounced (2), barely to overcome
(3) and not to overcome (4) with a worst score of 32 (arm,
hand, upper thigh, lower thigh both sides). A positive
Babinski sign was counted separately for each side (worst
score of 2). The clinical characteristics of the patients are
summarized in Table 1, progression of the ALSFRS-R prior
to MRI and the clinical status are displayed in Figure 1 and
Table 2, respectively.
Data acquisition
Images were acquired on a neuro-optimized 1.5-T GE
Signa Horizon LX (General Electric Company, Milwaukee,
WI, USA) using a 3-dimensional T1-weighted spoiled gra-
dient recalled echo (SPGR) sequence generating 124 con-
tiguous sagittal slices (RT 24 ms; TE 8 ms; flip angle 30°,
2 averages, acquisition time 13'10", in plane resolution
0.97 × 0.97 × 1.5 mm3). During scanning, all participants
were comfortably placed and their heads were fixated
within the headcoil with special cushions. All subjects
received additional T2-weighted images to exclude cere-
brovascular disease, which was normal in all subjects
studied according to standard clinical neuroradiological
criteria on visual inspection.
Preprocessing of structural data
Data were processed on a standard IBM-compatible PC
using SPM2 statistical parametric mapping software (Wel-
come Department of Cognitive Neurology, London) and
working in an analysis environment (MATLAB; the Math
Works Inc, Natick, Mass). The images were reoriented into
oblique axial slices aligned parallel to the anterior-poste-
rior commissural axis with the origin set to the anterior
commissure. An optimized version [26] of the VBM pro-
tocol was followed as recently described by our group
[34]. In brief, this involves first the creation of a custom-
ized template, followed by an iterative procedure for seg-
mentation and normalization of images. The resulting
images were resliced to a final voxel size of 1 mm3. Each
optimally normalized tissue-specific whole-brain model
was then segmented to isolate the corresponding tissue
compartment producing grey, white matter, and CSF
maps in MNI space. Voxel values in segmented images
were multiplied by the Jacobian determinants derived
from spatial normalization to provide intensity correction
for induced regional volumetric changes, thus preserving
within-voxel volumes that may have been altered during
Course of ALSFRS-R score prior to MRI Figure 1
Course of ALSFRS-R score prior to MRI. On average, 
ALSFRS was 39.6 ± 5.6 around the time of the scan reflecting 
the ALS cohort was mildly affected by disease. Note that 
some patients had barely gone into rapid progression 
whereas others have remained stable at a high score.BMC Neurology 2006, 6:17 http://www.biomedcentral.com/1471-2377/6/17
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non-linear normalization. The analysis of these 'modu-
lated' data tests for regional differences in absolute tissue
volume. The images were smoothed to 8 mm using a
FWHM (full width half-maximum) Gaussian filter to min-
imize individual gyral variations and to increase the statis-
tical validity of the analysis. As a consequence of
smoothing, each voxel in these 'modulated' images con-
tains an absolute measure of tissue volume from around
that voxel.
Statistical analysis
Processed images of each tissue class were analyzed in the
framework of the general linear model. This framework
allows the testing, on a voxel-by-voxel basis, of the null
hypothesis that the tissue volumes in the two populations
(patients and controls) are the same. The resulting statis-
tical parameters constitute a SPM of the t statistic (SPM
(t)). Group comparison of ALS patients and healthy con-
trols was performed in SPM2 using the model 'compare-
populations: one scan/subject (ANCOVA)'. During mod-
ulation we incorporated the correction for volume change
induced by spatial normalization. Therefore, it was appro-
priate to include the global mean voxel value of each tis-
sue class as a covariate to determine the regionally specific
pattern of loss or gain within each compartment as well as
to remove any variance due to differences in head size. As
previous VBM studies in ALS patients used density images
[20,22]., we performed additional group comparisons on
unmodulated data. Here, we controlled for global differ-
ences in voxel intensity across scans by proportional scal-
ing the global mean voxel intensity value.
Additionally, regression analyses with clinical measures
were explored using the SPM2 model 'single subject: cov-
ariates only'. As for the group comparisons, ANCOVA
with the mean voxel value was used to normalize image
intensity in the different tissue maps to allow identifica-
tion of the regional pattern of these correlations. Signifi-
cance levels were set at P < 0.05 on the voxel level,
corrected for multiple comparisons in the entire volume
using the false discovery rate method [35].
Results
Disease duration was taken from onset of symptoms,
which preceded the diagnosis of ALS for up to two years.
Diagnosis on study inclusion was suspected in some
cases, but eventually progressed to probable or definite on
follow up in all but one patient. Thus, our patient group
is considered mildly affected with an average ALSFRS of
~40 out of a maximum score of 48. On visual inspection
of the MR images no subject had focal atrophy of any
brain region which may have hindered alignment into
standard space or segmentation into grey matter, white
matter and CSF.
Group comparison of ALS patients (n = 17) and controls (n 
= 17)
ALS patients displayed significantly reduced grey matter
volumes (GMV) in the precentral gyrus, the postcentral
gyrus, parietal and frontal regions bilaterally (Figure 2,
Table 3). In the white matter tissue class, no significant
voxels were found. In CSF segments, no significant differ-
ences were detected.
Comparable results where found for unmodulated grey
matter segments at p < 0.001 uncorrected, but these
results did not reach the level of significance specified a
priori (Figure 3). No significant differences were found
when analysing unmodulated data for white matter and
CSF segments.
Correlation with clinical data
ALS patients clinical data and scores were separately corre-
lated with grey and white matter voxel values. Only the
ALSFRS-R as a validated marker of disease progression
correlated positively with GMV in the right medial frontal
gyrus corresponding to the dorsolateral prefrontal cortex
(Brodmann area 10, MNI x = 4, y = 65, z = 20; T = 4.95).
Disease duration and onset (bulbar/limb) were not
reflected in a specific pattern of atrophy. There was no sig-
nificant correlation with PR/mth(t), PR/mth(6), strength
(tested separately for each extremity, upper and lower
extremities and all extremities), lower motoneuron signs
(muscle atrophy, fasciculations), upper motoneuron signs
(increased reflexes, spasticity, Babinski sign) or bulbar
signs.
Discussion
Voxel-based mapping of structural brain alterations in
mildly affected ALS patients revealed statistically signifi-
cant reductions of grey matter volumes in the primary sen-
sorimotor cortex and frontal lobe bilaterally. There was no
correlation between the clinical expression and brain
morphology in the patient group except for the ALSFRS-R
which correlated with extramotor involvement in the
right dorsolateral prefrontal cortex.
Motor cortex atrophy as a prominent feature of ALS
The most prominent finding of our study was bilateral
atrophy of the motor strip which extended to primary sen-
sory areas. Loss of giant pyramidal Betz' cells has been
described as the pathologic hallmark of the ALS disease
process [36]. Furthermore, it has been shown that the
number of cortical neurons in ALS is not reduced [37],
and some evidence suggests a change in cell body shape
rather than a loss of neurons [38]. These findings repre-
sent the end point of structural change, while the present
study demonstrates that changes can be detected in vivo
even in mildly affected patients, using sensitive imaging
methods. In keeping with the increasing interest in theBMC Neurology 2006, 6:17 http://www.biomedcentral.com/1471-2377/6/17
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comprehensive assessment of ALS brain anatomy, we
used highly automated voxel-based morphometric proce-
dures and examined the entire cerebral parenchyma with
a conservative statistical approach. We adopted an
improved method for modulating data that allowed direct
volume measurements. In our analysis, voxel values spe-
cifically expressed regional variations in the absolute
amount of brain tissue, in contrast with previous voxel-
based studies in which the interpretation of results was
not self-evident, as voxel-values expressed variations in
structure shape and tissue composition [20-22].
Our results are well in line with a recent VBM study in ALS
and frontotemporal lobar degeneration [23]. Using mod-
ulated grey matter segments in their analysis, the authors
detected marked frontal atrophy and considerable motor
cortex atrophy although age-related variance was not ade-
quately represented in the control group. Interestingly,
those morphometric imaging studies which failed to
show considerable grey matter atrophy showed extensive
white matter involvement. Following an optimized proto-
col within VBM investigating the density (unmodulated
data) of grey and white matter segments, Kassubek and
colleagues [22] found regional decreased grey matter den-
sity in the right-hemispheric primary motor cortex and left
medial frontal gyrus in 22 patients with definite ALS.
However, while there were few differences in grey matter,
extensive changes within white matter particularly along
the bilateral CST and in extramotor areas were found in
line with neuropathological investigations [39,40] and
previous quantitative volumetric MRI studies [20,21,41].
This raises the question as to whether GMV reductions in
our study are emphasized at the expense of detecting
Regional grey matter atrophy in ALS patients compared to controls Figure 2
Regional grey matter atrophy in ALS patients compared to controls. Group comparison of 17 ALS patients versus 
17 healthy controls showed regional grey matter atrophy in the precentral and postcentral gyrus bilaterally, which extended 
from the primary motor cortex to premotor, parietal and frontal regions bilaterally (displayed at p = 0.001, uncorrected, 
extended threshold 100 voxels). The color bar represents the T-score. The differences between the groups are superimposed 
on a standard normalized T1-weighted image. Images are shown in neurological convention.BMC Neurology 2006, 6:17 http://www.biomedcentral.com/1471-2377/6/17
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white matter changes. Although neuropathology can only
reveal end-stage changes, white matter involvement is
considered to be a significant factor in ALS. Degenerating
fibres are not only present in the precentral gyrus and
paracentral lobule, but they are also abundant in the post-
central gyrus, and occur in considerable numbers in the
adjacent parietal and frontal gyri [39]. As revealed by a
recent volumetric MRI study, white matter reductions
within motor and non-motor areas are more extensive in
cognitively impaired than unimpaired ALS patients com-
pared with control subjects [21]. In the present study, no
significant white matter alterations were found. Apart
from technical differences, these discrepant findings may
be related to our cohort of ALS subjects which was consid-
ered to be mildly affected by disease. Furthermore, no
overt cognitive abnormalities were present although the
patients had no formal neuropsychological testing.
Thus, the discrepancy within all published morphometric
studies in ALS so far may be related to differences in the
relatively small cohorts of patients, and several methodo-
logical factors within the data analysis process. For exam-
ple, as indicated in Figure 3 we have also analyzed our
data using density grey matter segments and have found
nearly similar results as with modulated data. However,
these results were derived at p < 0.001, uncorrected and
did not survive the correction for multiple comparisons
on the voxel level specified a priori. This is mandatory in
VBM studies because the data used for these analyses are
not exactly normally distributed (for details see [25]).
Extramotor involvement in ALS
There is a growing body of evidence for extramotor
involvement ALS by pathological [42,43], neuropsycho-
logical [44] and in vivo imaging research using PET
[18,45]. Furthermore, in line with our results, alterations
of the frontal lobe have been reliably demonstrated by
previous quantitative volumetric MRI studies [20,21]
where these findings were discussed in detail. As a new
finding of our study, there was considerable atrophy of
the postcentral gyrus bilaterally. Although the cardinal
pathological features of ALS include loss of the giant Betz
cells in layer V of the primary motor cortex; the anterior
horn cells in the spinal cord and degeneration of the cor-
ticospinal tracts, other cortical areas seem to be involved
by neurodegeneration to varying degrees. A recent PET
study has shown that cortical involvement is not restricted
to the primary motor cortex by demonstrating widespread
reductions in cortical binding of [11C] flumazenil in ALS
patients. Reduced binding of [11C] flumazenil which is
an antagonist at the benzodiazepine subunit of the
GABAA  receptor was found in multiple cortical areas
including primary and secondary motor areas as well as
mesial premotor and parietal cortices [18]. Furthermore,
previous PET studies using [18F]2-fluoro-2-deoxyglucose
have demonstrated predominant reductions in glucose
metabolism as well as reductions in regional cerebral
blood flow (rCBF) in the primary sensorimotor cortex and
adjacent premotor and parietal areas in patients with clas-
sical ALS [46,47]. As sensory pathways in ALS are more or
less intact [48,49]., grey matter atrophy of the postcentral
gyrus in ALS is likely to reflect changes at the cortical level
Table 3: Relative decrease in grey matter volumes in ALS patients compared to controls
Cluster Side Region Brodmann's Area MNI-Space T-Value P-Value
xyz
1 R precentral gyrus 4 61 -6 20 7.29 0.011
R precentral gyrus 6 60 2 28 5.85 0.032
R precentral gyrus 6 60 -13 42 5.51 0.032
2 L inferior parietal lobule 40 -51 -38 47 5.51 0.032
L postcentral gyrus 3 -62 -18 33 4.93 0.032
L postcentral gyrus 3 -58 -15 47 4.85 0.033
3 R middle frontal gyrus 6 49 3 49 5.39 0.032
4 L middle frontal gyrus 6 -46 0 43 5.09 0.032
5 R postcentral gyrus 3 41 -25 46 5.03 0.032
6 R postcentral gyrus 3 64 -23 41 5.01 0.032
R inferior parietal lobule 40 44 -58 51 4.48 0.039
7 R superior frontal gyrus 8 36 19 53 4.99 0.032
8 L postcentral gyrus 1 52 -23 54 4.83 0.033
9 L middle frontal gyrus 9 42 33 30 4.64 0.035
L superior frontal gyrus 9 -36 36 38 4.21 0.048
10 R superior frontal gyrus 8 9 34 57 4.55 0.037
Coordinates (in mm) of peak group differences in MNI space (Montreal Neurological Institute, http://www.bic.mni.mcgill.ca) are given for 
information. Significant local maxima more than 8 mm apart were translated to brain anatomy by converting their coordinates from MNI space to 
Talairach space http://ric.uthscsa.edu/projects/talairachdaemon.html allowing for a search radius of 3 mm for nearest grey matter.BMC Neurology 2006, 6:17 http://www.biomedcentral.com/1471-2377/6/17
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due to progressive degeneration of the upper motor neu-
ron (UMN) in ALS rather than secondary to peripheral
conduction delay. Supporting this assumption, animal
studies demonstrated a decrease in the density of inhibi-
tory GABAA receptors resulting in an increased excitability
in multiple cortical areas which are related with regard to
their connections to experimentally injured brain areas in
rats [50]. Effects remote from the site of injury are not sur-
prising given that neurons in any damaged region of the
cortex have reciprocal synaptic connections with neurons
in other brain regions. Such remote effects may poten-
tially be responsible for secondary progressive brain
pathology in ALS extending beyond the initially affected
neural system [45].
Correlations with clinical status
We did not find a correlation of brain morphology and
relevant clinical variables which were thoroughly quanti-
fied (Table 2) in the ALS patients. The lack of correlation
with disease duration and lower motor neuron signs is not
surprising, given the heterogeneity of the condition and
the small sample size, and the lack of correlation with
UMN dysfunction probably reflects the limited range
scores in the patient sample. In addition, this could be
attributed to the small percentage of affected cells and
physiologic variation in central gyral anatomy despite
adequate smoothing of the data. Only the ALSFRS-R score
which largely tests activities of daily living and correlates
with both objective measures of disease status and levels
of disability [33] displayed a significant positive correla-
tion with regional atrophy in grey matter of the right dor-
solateral prefrontal cortex (DLFPC). Although we had no
formal neuropsychological testing, the cognitive abnor-
malities of ALS are now well characterized [44,51]. Frank
dementia is rare in ALS and usually frontotemporal in
type, but more subtle cognitive deficits frequently relating
to executive function can be reliably identified in up to
50% patients and appear relatively early on in the course
of the disease [44]. Previous morphometric and func-
tional imaging studies have revealed changes in the
DLFPC, which is involved in executive functioning, even
in cognitively unimpaired patients [21,52]. Overall, these
changes were more marked when cognitively impaired
patients with evidence of executive and memory dysfunc-
tion were investigated. This led to the assumption that
those functional and structural abnormalities in the
medial prefrontal cortex which corresponds to this profile
of principally executive dysfunction may precede cogni-
tive change [21]. The positive correlation with disease sta-
tus as expressed by the ALSFRS-R and GMV reduction in
the right DLFPC revealed by our study is further support-
ive of this assumption.
Conclusion
Assessing regional grey matter volumes in mildly affected
ALS patients, sensorimotor cortex atrophy can be regarded
as a prominent feature of the disease. Supporting the con-
cept of ALS being a multisytem disorder, our study pro-
Group comparison of unmodulated and modulated grey matter segments Figure 3
Group comparison of unmodulated and modulated grey matter segments. Group differences of grey matter den-
sitiy reductions (unmodulated data, A) and regional grey matter volumes (modulated data, B) in ALS patients versus controls 
are displayed within a 'glass brain' view. Note that only the comparison of modulated data survived the correction for multiple 
comparisons specified a priori. Images are displayed at p = 0.001, uncorrected, extended threshold 100 voxels and shown in 
neurological convention.BMC Neurology 2006, 6:17 http://www.biomedcentral.com/1471-2377/6/17
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vides further evidence for extramotor involvement which
is widespread. The lack of correlation with common clin-
ical variables probably reflects the fact that ALS underlies
a heterogeneous disease process. Longitudinal studies are
required to further clarify the time course and distribution
of grey and white matter pathology during the course of
ALS.
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